Concepedia

Publication | Open Access

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

DOIFull Paper Access

611

Citations

21

References

2021

Year

Emmanuel B. Walter, Kawsar R. Talaat, Charu Sabharwal, Alejandra Gurtman, Stephen Lockhart, Grant Paulsen, Elizabeth D. Barnett, Flor M. Muñoz, Yvonne Maldonado, Barbara Pahud,
New England Journal of Medicine

Abstract

A Covid-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).

References

YearCitations

Page 1